[Project of invention] [ERBISOL®] [Extra ERBISOL®] [ERBISOL ® UItrapharm] [Publications] [Recomendations] [Doctors' Experience] [Dissertations] [Contact] [News]

Medicus curat, Natura sanat!


Erbisol - inspector and restorer

From Author

1. Nikolaenko A. Conceptual approaches to development of highly effective Erbisol® drugs of new generation. (159Kb, PDF). ENG

2. Nikolaenko A. General characteristic of Erbisol class preperations. (150Kb, PDF). RU

Gastroenterology

1. Svintsytsky A.S., Dzeman M.I., Kozak N.P., Bazyka D.A., Shylo A.V. Clinicoimmunologic aspects concerning use of new Ukrainian medicine Erbisol® in combined therapy of patients with hepatitis. (12Kb, PDF). ENG

2. Dzeman M. Five-year experience of preparation Erbisol® application in gastroenterology practice. (150Kb, PDF). RU

3. Koveshnikov O. The estimation of efficiency of Erbіsol® and Мanaks combination in the rehabilitation period of patients with gallstones (Cholelithiasis) disease after laparoscopic cholecystectomy. (58Кb, PDF). UA

Gynecology and obstetrics

1. Tatarchukчук T., Zdanovich I., Kosej N., Gavrilenko T., Kornilina E., Nikolayenko A. Clinical and immunological aspects of Erbisol® application in complex treatment of patients with leyomyoma uteri. (199Kb, PDF). RU

2. Gavrilenko T., Kornilina E., Yakushko L., Tatarchuk T., Zdanovich I., Kosej N. Peculiarities of Erbisol® Influence on immunological indices in complex treatment of women with leyomyoma uteri combined with dishormonal pathology of mammary and thyroid glands. (205Kb, PDF). UA

3. Tsibisova I. Influence of Erbisol® in combination with enterosorbents on the level of circulating immune complexes and "middle-weight" molecules in pregnant patients with exacerbation of chronic hepatobiliar pathology. (192Kb, PDF). UA

Immunology

1. Drannyk G., Kurchenko A., Fesenkova V., Dyagel I., Kornilina E., Nikolayenko A., Gladkiy A. Study of influence of Erbisol® class preparation on cytokines production by mononuclear cells of periferial blood of healthy donors and patients with (242Kb, PDF). Erbisol® Ultrapharm. RU

2. Bazuka A., Gladkiy A., Kornilina E., Nikolaenko A. Peculiarities of influence of Erbisol® class preparations on expression of surface markers of blood cells of healthy donors and patients with immunodepression of cell immunity in vitro and progress of treatment. (261Kb, PDF). RU

3. Drannyk G., Kurchenko A., Fesenkova V., Nikolayenko A. Influence of Erbisol class preparation on cytokines production in patients with relapsed herpes. (137Kb, PDF). Erbisol® - Erbisol® Ultrapharm. RU

4. Fesenkova V., Drannyk D., Driyanska V., Papakina V., Vashenko V. In vitro examination of influence of preparation Erbisol® on 1-st type T-helpers production of interleikyn-2 and gamma-interferon in healthy donors, V. Fesenkova, G. Drannyk, V. Driyanska, V. Papakina, S. Vashenko. (255Kb, PDF). UA

5. Drannyk G., Fesenkova V., Driyanska V., Papakina V., Nikolaenko O., Nazar O. In vitro examination of influence of preparation Erbisol® on functional activity of II-nd type T-helpers production of IL-4 and IL-10. (247Kb, PDF). UA

6. Drannyk G., Svydro E., Kurchenko A., Vagalyuk V., Fesenkova V., Savchenko V. Influence of Erbisol® Ultrapharm om production of TNF-alpha, IL-12 и Interferon-gamma in patients with recidivic HSV infection. (181Kb, PDF). Erbisol® Ultrapharm (immunology). RU

7. Drannyk G., Svydro E., Kurchenko A., Vagalyuk L., Fesenkova V. Influence of Erbisol® Ultrapharm on IL-4, IL-10 production and expression of activational molecules in patients with chronic recidivic HSV infection. (173Kb, PDF). Erbisol® (immunology). RU

8. Kornilina E., Nikolayenko A.,Vovk. V, Solyanik I., Bazuka A. New medicine in treatment of chronic hepatitis C (part I). (185Kb, PDF). Erbisol® Ultrapharm (immunology). RU

9. Girina O., Vitik L., Romanuk L., Osipova L., Grishilo P. The optimization of treatment of patients with polinose by application of preparation Extra Erbisol®. (115Kb, PDF). Extra Erbisol®. RU

Infectious Diseases

1. Ivaskiva E., Orlenko V., Efimov A. The application of Erbisol® in complex treatment of urinary ways infections in patients with diabetes mellitus. (132Кb, PDF). RU

Viral Hepatites

1. Vovk A.D. Tatjanko N.V. Erbisol® for treating patients with viral hepatitis B: an experience. (93Kb, PDF). RU

2. Vovk C.A., Solyanyk I., Matyash V., Yasenovy S., Bazuka A., Boltina I., Nikolayenko A. Erbisol® Ultrapharm in treatment of chronic hepatitis. (257Kb, PDF). Erbisol® Ultrapharm (clinic). RU

3. Kornilina E.M., Nikolayenko A.N., Vovk A.D., Solyanik I.V., Bazuka A.D. New medicine in treatment of chronic hepatitis C (part I). (185Kb, PDF). Erbisol® Ultrapharm (immunology). RU

4. Boltina I.V., Vovk A.D., Solyanik I.V., Kornilina E.M., Nikolayenko A.N. New medicine in treatment of chronic hepatitis C (part II). (205Kb, PDF). Erbisol® Ultrapharm (mutagenic effect). RU

5. Vovk C. A., Yasenovy S., Bazuka A., Nikolayenko A., Kornilina E., Yanchenko V., Solyanik I., Dyachenko P. New approach in treatment of chronic hepatitis. (116Kb, PDF). Erbisol® Ultrapharm. RU

Herpetic infection

1. Markov I. Combined therapy of chronic recidivic HSV infection. (371Kb, PDF). RU

2. Markov I.S. Combined therapy of chronic recurrent herpetic (HSV1/2) infection. (13Кb, PDF). ENG

3. Markov I.S. Clinical experience of applying of Cymeven (Ganciclovir) for medical treatment of cytomegaloviral infection inherent to immunecompetent patients. (46Кb, PDF). ENG

4. Drannyk G., Kucherenko A., Svidro E., Vagalyuk L., Fesenkova V., Savchenko V. Application of immunomodulator Erbisol® Ultrapharm in patients with HSV infection. (283Kb, PDF). Erbisol® Ultrapharm (clinic). RU

5. Drannyk G., Svydro E., Kurchenko A., Vagalyuk L., Fesenkova V., Savchenko V. Influence of Erbisol® Ultrapharm on production of TNF-alpha, IL-12 и Interferon-gamma in patients with recidivic HSV infection. (181Kb, PDF). Erbisol® Ultrapharm (immunology). RU

6. Drannyk G., Svydro E., Kurchenko A., Vagalyuk V., Fesenkova V. Influence of Erbisol® Ultrapharm on IL-4, IL-10 production and expression of activational molecules in patients with chronic recidivic HSV infection. (173Kb, PDF). Erbisol® Ultrapharm(immunology). RU

7. Drannik G., Kurchenko A., Fesenkova V., Nikolaenko A. An influence of preparation Erbisol® Ultrapharm on the production of cytokines in patients with relapsing herpetic infection. (137Kb, PDF). Эрбисол®- Erbisol® Ultrapharm. RU

Cardiology

1. Fomina A., Shipulin V. Report about of clinical test of preparation Erbisol® in patients with atherosclerosis. (116Kb, PDF). RU

2. Karpenko L.N., Tutov Y.N., Melnik U.I. Effect of Extra Erbisol® on myocardium disfunction and Q–T interval dispersion with ischemic heart disease. (194Кb, PDF). Extra Erbisol®. RU

Neurology

1. Unich P., Vinnichuk S., Nikolayenko A. Extra Erbisol® in complex therapy of patients with disseminative sclerosis. (220Kb, PDF). Extra Erbisol®. UA

2. Vinnichuk S, Lysyanyj N., Unich P., Myalovitskaya E. Clinical effectiveness of praparation Erbisol® in complex therapy of patients with dissiminative sclerosis. (220Kb, PDF). RU

3. Karpenko L., Nikolayenko A., Kaminsky A., Lomaka V. Effectiveness of complex influence of Extra Erbisol® on functional indices of cerebral activity in eldery patients. (142Kb, PDF). Extra Erbisol®. RU

4. Karpenko L., Kaminsky A., Lomako V., Melnik U. New approach to the treatment and prophilaxis of ischemic insult. (176Kb, PDF). Extra Erbisol®. RU

Oncology

1. Drannik G. Kurchenko A., Fesenko V., Dyagel I., Kornilina E., Nikolaenko A. Gladky A. Influence study of Erbisol® preparates on production of blood monobuclears in healthy donors and oncologic patients. (243Kb, PDF). Erbisol® - Erbisol® Ultrapharm. RU

2. Bazika D.A., Gladky A.V., Коrnilina Е.М., Nikolayenko A.N. Influence particularies of Erbisol® preparations on expression of surface markers of cell blood in healthy donors and patients with cell immunity immunodepression in vitro and dinamics of treatment. (261Kb, PDF). Erbisol® - Erbisol® Ultrapharm. RU

3. Shalimov S., Gladkiy A., Litvinenko A., Nikolayenko A., Gladkaya L., Bazuka D., Yatsenko L. Erbisol® in schemes of complex treatment of malignant tumors. (239Kb, PDF). RU

4. Shalimov S., Gladkiy A., Litvinenko A., Nikolayenko A., Gladkaya L., Basyka D., Yazenko L., Vapnichnaya. I. Long-term results of application of Erbisol® in a complex of malignant tumors treatment. (230Kb, PDF). RU

5. Information Letter № 97 - 99 about innovations in the system of Health Protection. Ministry of Health of Ukraine. (106Kb, PDF). RU

6. Gladkiy A. Chronometrated regional chemotherapy of metastatic lesions of liver. (170Kb, PDF). RU

7. Gladkiy A. Applications of Erbisol® Ultrapharm in regional chemotherapy of malignant tumors. (182Kb, PDF) Erbisol® Ultrapharm. RU

8. Stepula V., Kuznechov O., Marcinkovskaja N. Application of Erbisol® on a background the chemotherapy in patients with cancer of ovaries. (187Кb, PDF). RU

9. A. N. Nikolaenko, N. L. Cheremshenko, G. V. Didenko, G. S. Lysovenko, G. P. Potebnya. Antitumoral aktivity of "ERBISOL®" class medications in vitro and in vivo. R. E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Science of Ukraine Ltd "ERBIS", Kiev, Ukraine (586Кb, PDF). ENG

 

Pulmonology

1. Kogosova L., Nikolaenko A., Kovalenko N., Cigankova L., Novosad F., Matvienko Y., Gotsh T. Clinico-immunologic efficiency of Erbisol® in treatment of patients with bronchial asthma. (290Кb, PDF). RU

2. Dzubik A., Kogosova L., Kapitan G., Demchenko E. The influence of Erbisol®on the state of system and local immunity in patients with chronic obstructive bronchitis. (179Кb, PDF). RU

Stomatology

1. Danchenko A., Borisenko. Clinical and laboratorial examination of Erbisol® application in complex treatment of generalized parodontitis. (110Kb, PDF). RU

2. Zhirova V. Indices of general lipides in erythrocytes' membranes and plasma in patients with gingivitis with the background of accompanying diseases and also after antioxydative (131Kb, PDF). RU

3. Dzeman N. Achievements and prospects of Erbisol® application in stomatology. (147Кb, PDF). RU

4. Dzeman N., Lesnuhina A., Grig N. Correction expedience of total adaptation reactions organism in complex treatment of general parodontitis. (168 Kb, PDF). RU

Ophthalmology

1. Pasechnikova N., Zborovskaya A. APPLICATION OF “ERBISOL®” IN TREATMENT OF DISEASES OF CORNEA “Eye Microsurgery Center” Kiev, Ukraine. (58Kb, PDF). ENG

Therapy

1. Kulikova E. Application of Erbisol® in complex treatment of patients with chronic laryngitis combined with autoimmune thyreoiditis. (174Kb, PDF). RU

Surgery

1. Sukharev I., Nikulnikov P. Report on clinical application of Erbisol® in complex treatment of festering wounds and trophic ulcers in vascular surgery. (104Kb, PDF). RU

2. Roshin G., Satmari V., Karpenko L. Analysis of clinical application of Erbil in the department of cardio-vasular surgery in patients with vascular diseases. (97Kb, PDF). RU

3. Ankin L., Nikitin P., Skobenko A. Report on clinical tests of Erbisol®. (108Kb, PDF). RU

4. Gladkiy O., Gladka L., Nikolaenko A., Rodsaevskiy S., Boiko A. Erbisol® usage in treatment cysts. (132Kb, PDF). UA

Endocrinology

1. Bodnar P.N., Lopushenko N.I., Nifontova L.V. Preparation Erbisol® in therapy of insulin-dependent diabetes mellitus. (143Kb, PDF). ENG

2. Konah V., Bodnar P., Nikolaenko A. Medical effect of Erbisol®at autoimmune thyroiditis. (115Кb, PDF). RU

3. Bodnar P., Peshko A., Mihalchishin G., Kononenko N., Kirienko D., Lopushenko N. Pharmacotherapy insulin of a dependent diabetes. (132Кb, PDF). UA

4. Ivaskiva E., Prlenko V., Efimov A. The application of Erbisol® in complex treatment of urinary ways infections in patients with diabetes mellitus. (132Кb, PDF). RU

Genetic Aspects

1. Boltina I.V., Vovk A.D., Solyanik I.V., Kornilina E.M., Nikolayenko A.N. New medicine in treatment of chronic hepatitis C (part II). (205Kb, PDF). Erbisol® Ultrapharm (mutagenic effect). RU

2. Boltina I., Nikolayenko A. Study of activity of Erbisol® Ultrapharm in test of induction of chromosome aberration in the culture of lymphocytes of peripherial blood in vitro with and without metabolic activation. (243Kb, PDF). Erbisol® Ultrapharm. RU

Debatable club

1. Gladkiy O., Kurik M., Dobrovolska Y., Gladka L. The structured water. Methods of parameters determination and possibilities of application. (265Kb, PDF). UA

Upwards pages


Acrobat Reader 5.0+ is necessary to view PDF files


Medicus curat, Natura sanat!


[Project of invention] [ERBISOL®] [Extra ERBISOL®] [ERBISOL ® UItrapharm] [Publications] [Recomendations] [Doctors' Experience] [Dissertations] [Contact] [News]